INCOG BioPharma Services Announces Significant 2025 Facility Expansion Projects

• INCOG BioPharma Services is expanding its Fishers, Indiana facility with a 113,000-square-foot addition, adding device assembly, labeling, and packaging capabilities.

• The company has installed a high-speed Optima syringe and cartridge filling line, increasing capacity by 100 million units, and plans to grow its workforce to over 350 employees.

INCOG BioPharma Services has announced strategic expansion projects set for 2025, including facility growth, increased filling capacity, and workforce expansion. The Fishers, Indiana-based CDMO is enhancing its sterile injectable manufacturing capabilities to meet growing industry demand.

The company’s ongoing facility expansion includes a 113,000-square-foot addition adjacent to its current site. This new space will support automated device assembly for autoinjectors, pens, wearable injectors, and syringe accessorizing, alongside new labeling and final packaging capabilities.

As part of its manufacturing scale-up, INCOG BioPharma has installed a high-speed Optima syringe and cartridge filling line, which adds 100 million units of capacity. The line, delivered last November, is set to be GMP-ready this September.

“Our new high-speed Optima filling line represents a significant step forward for INCOG, allowing us to efficiently fill both syringes and cartridges for large-scale commercial projects,” said Cory Lewis, CEO and President of INCOG. “This investment, coupled with expanding the facility and commissioning automated device assembly and packaging lines, reinforces our commitment to providing end-to-end solutions that meet the evolving needs of our clients.”

Alongside these infrastructure developments, the company is launching a strategic hiring initiative. By the end of summer 2025, INCOG BioPharma expects to employ more than 350 people across manufacturing, quality assurance, and client support roles.

The expansion builds on a year of achievements in 2024, including a successful FDA inspection with zero observations, 20 customer audits, and the installation of additional manufacturing capabilities.